Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Mark Hertzberg, Maher K. Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D. Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F. Seymour, Michael S. Hofman, and Rodney J. Hicks

Disclosures: 1. Research Support: This study was supported in part by Roche Products Pty. Ltd, Amgen Australia Pty. Ltd, and Bayer Australia Ltd. 2. Mark Hertzberg Honoraria / advisory committee - Celgene, Amgen, Gilead, Janssen, Takeda, BMS. John F Seymour Research funding - Janssen & AbbVie Honoraria / advisory committee - AbbVie, BMS, Celgene, Genentech, Gilead, Incyte, Infinity, Janssen, Roche, Takeda Costs of travel - AbbVie, Roche, Celgene Andrew Grigg Honoraria / advisory committee - Amgen, Roche Ian Lewis Honoraria; Roche. Travel Support; Roche, Amgen Gavin Cull Advisory - Janssen Travel - Amgen Shir-Jing Travel Celgene 3. No patents or copyright pending